

# Molgen

## Lefitolimod partnership close to completion

Molgen has signed term sheets for a global partnership with Oncologie for its lead asset, lefitolimod. The deal is expected to complete in Q119, and in the near term Molgen expects to receive €23m from the agreement in a combination of R&D funding, cash payment and bond issues. Sensitivity remains around Oncologie, which is an early-stage biotech with \$16m in seed funding. Molgen completed a capital raise in which it received gross proceeds of €8.2m. Focus remains on data from the Phase III IMPALA trial in metastatic colorectal cancer (mCRC), expected in 2019. We value Molgen at €179m (€19.3/share).

### Oncologie: Challenges remain with early partner

Oncologie will lead the global development of lefitolimod (TLR9 agonist). Near-term financing is split such that Molgen has received €3m in cash and €2m in interest-free convertible bonds, with a further €2m bond expected once the final contract is signed. It also expects €7m in budgeted expenses (for IMPALA) and €9m in funding for additional combination studies in the short term. Longer-term considerations involve over €1bn and a tiered royalty rate on net sales (peak 16%). Oncologie must finish a mid-double digit million funding round to enable the deal to be closed.

### IMPALA: Phase III readout in 2019

Molgen now forecasts that IMPALA, a 549-patient (enrolled), two-arm, randomised pivotal Phase III trial for the maintenance treatment of mCRC patients, will read out in 2019. Near-term catalysts could be provided by initial (safety) data from the ICI combination trial and the initiation of a new study with lefitolimod in HIV (TITAN).

### Financials: Cash reach until mid-2019

Net loss in H118 was reduced to €4.8m (H117: €10.7m) as a result of a reduction in R&D costs and the initial payment of €3m from Oncologie. Estimated current net cash of c €12m (includes Oncologie financing paid to date and €8.2m gross capital raise) should fund Molgen into mid-2019. Molgen has received potential termination notices for its 2016/24 and 2017/25 convertible bonds, an agreement with the principal bond holder has been reached that will avert immediate payment of both convertible bonds at a total amount of €6.6m. The terms and conditions of both bonds have been amended and will be submitted to the creditors for approval.

### Valuation: €179m (€19.3/share)

We value Molgen at €179m (€19.3/share). We have rolled forward our model, which is based on a risk-adjusted rNPV of lefitolimod across a range of indications and regions. Additionally, we have updated it for the €8.2m gross capital raise.

#### Edison estimates


Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/16	0.0	(20.8)	(4.22)	0.0	N/A	N/A
12/17	0.0	(19.3)	(2.81)	0.0	N/A	N/A
12/18e	6.0	(11.1)	(1.19)	0.0	N/A	N/A
12/19e	7.0	(9.7)	(1.05)	0.0	N/A	N/A

Source: Edison Investment Research

## Pharma & biotech

**Price** €3.0  
**Market cap** €28m

#### Share price graph



#### Share details

Code	MGN
Shares in issue	9.27m
Net cash (€) as at 30 June 2018	0.7m

#### Business description

Molgen is a German biopharmaceutical company developing novel biopharmaceuticals. Lead product lefitolimod (TLR9 agonist) is being evaluated in metastatic colorectal cancer maintenance, small cell lung cancer maintenance, HIV and a combination trial in advanced solid malignancies.

#### Bull

- Positive safety profile of lefitolimod.
- iPharma collaboration could bring in significant revenue.
- Phase III IMPALA mCRC trial holds long-term potential.

#### Bear

- Limited current cash reach into mid-2019.
- Pipeline currently focused on one asset (lefitolimod).
- Company currently reliant on success of Phase III IMPALA readout.

#### Analysts

Dr Daniel Wilkinson	+44 (0)20 3077 5734
Dr Susie Jana	+44 (0)20 3077 5700
Dr Sean Conroy	+44 (0) 20 3681 2534

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

**Molgen is a client of Edison  
Investment Research Limited**

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2014]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.